Shares of RegenCell Bioscience (ticker: $RGC), a biotech company, have surged dramatically from around $3 to over $800 within a two-month period, representing an increase exceeding 20,000%. This rapid price escalation has drawn skepticism and concerns from market participants, with some labeling the stock as a potential fraud linked to Chinese companies. The market capitalization of RegenCell Bioscience has reached approximately $10 billion amid this surge. Investors have noted the extreme volatility, with predictions that the stock price could eventually crash back below $100. Comparisons have been made to other volatile stocks such as $HKD, which rose from $12 to $2,555 before a sharp decline. Meanwhile, another stock, $MFI, has also seen recent price gains, reportedly due to the purchase of all Class B shares by an undisclosed buyer, prompting speculation of a coordinated price pump. The unusual price movements have led to calls for regulatory intervention, including suggestions for an interest rate hike to curb such market behaviors.